Vernalis and Novartis form cancer research collaboration
UK company Vernalis has formed a research collaboration with the Novartis Institutes for BioMedical Research (NIBRI), in Cambridge, Massachusetts, to investigate inhibitors of a target implicated in the progression of a range of cancers.
UK company Vernalis has formed a research collaboration with the Novartis Institutes for BioMedical Research (NIBRI), in Cambridge, Massachusetts, to investigate inhibitors of a target implicated in the progression of a range of cancers.
Under the agreement Vernalis will provide elements of its ongoing oncology research to NIBRI for an initial six-month evaluation period, after which NIBRI will have the right to enter a longer-term r&d collaboration.
During the evaluation period NIBRI will both conduct its own research and fund research at Vernalis' laboratories in Cambridge, UK. If NIBRI subsequently exercises its option to enter the longer-term research and development agreement, it will make further payments to Vernalis which may include an equity investment in Vernalis.